ClinicalTrials.gg
CompletedNCT00326053PARADEUpdated Jan 24, 2011

Prevention of Asthma Relapse After Discharge From Emergency

A Phase 3 interventional study of Budesonide/formoterol in Asthma, sponsored by AstraZeneca. Completed at 20 sites in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-01-24.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Planned enrollment
21st of 108
600 · median 124
Started
2006
with 7 others
Phase 3
51 of 110
3 open now
Registered
20th of 110
by date
Lead sponsor
41 of 110
AstraZeneca

Among the 110 studies testing budesonide in Asthma, this one is the 21st largest by planned enrollment of the 108 interventional ones that give a count, is one of 8 that started in 2006, is one of 51 in phase 3, and was the 20th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

The purpose of this study is to compare the Symbicort® Turbuhaler® to both Pulmicort® Turbuhaler® and Bricanyl® Turbuhaler® for the treatment of asthma after discharge from the emergency room

03

Conditions studied

  • Asthma

Keywords

  • Asthma Reoccurrence
  • Acute Asthma
  • Patient Discharge
  • Emergency Service, Hospital
  • Asthma Exacerbation
  • Asthma Relapse
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 - 65 years of age
  • Presenting at a study emergency department with an asthma exacerbation

Exclusion criteria

Exclusion Criteria:

  • Admission to hospital
  • Patients receiving more than 2000 µg/day of beclomethasone equivalent inhaled (1000 µg/day fluticasone or 1600 µg/day budesonide)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
600 participants (estimated)

Interventions

06

What researchers measure

Primary outcomes

  1. Time to first asthma relapse

Secondary outcomes

  1. Mean use of reliever medication

  2. Asthma Control Questionnaire (ACQ) score

  3. Complete AE and SAE collection

07

Study locations

20 sites
  • Research Site
    Calgary, Alberta, Canada
  • Research Site
    Edmonton, Alberta, Canada
  • Research Site
    Lethbridge, Alberta, Canada
  • Research Site
    St. Albert, Alberta, Canada
  • Research Site
    Nanaimo, British Columbia, Canada
  • Research Site
    Vancouver, British Columbia, Canada
  • Research Site
    Halifax, Nova Scotia, Canada
  • Research Site
    Truro, Nova Scotia, Canada
  • Research Site
    Hamilton, Ontario, Canada
  • Research Site
    Kingston, Ontario, Canada
  • Research Site
    Niagara Falls, Ontario, Canada
  • Research Site
    Ottawa, Ontario, Canada
  • Research Site
    Thunder Bay, Ontario, Canada
  • Research Site
    Toronto, Ontario, Canada
  • Research Site
    Charlottetown, Prince Edward Island, Canada
  • Research Site
    La Malbaie, Quebec, Canada
  • Research Site
    Montreal, Quebec, Canada
  • Research Site
    Ste-Foy, Quebec, Canada
  • Research Site
    Saskatoon, Saskatchewan, Canada
  • Research Site
    Quebec, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006 and a completion of May 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2006
First posted
May 16, 2006
Start
May 2006
CompletionActual
May 2007
Last update
Jan 24, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00326053
Lead sponsor
AstraZeneca
First posted
May 16, 2006
Start date
May 2006
Completion
May 2007
Last update
Jan 24, 2011

Study contacts

Gloria Jordana, MD
study director · AstraZeneca
Brian Rowe, MD
principal investigator · University of Alberta
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Budesonide · Formoterol

Start the discussion